Literature DB >> 8216515

Angioedema in the emergency department: the impact of angiotensin-converting enzyme inhibitors.

E C Pigman1, J L Scott.   

Abstract

Angiotensin-converting enzyme (ACE) inhibitors have been reported to cause angioedema. The purpose of this study was to establish what proportion of patients who present to the emergency department (ED) with angioedema were concomitantly taking any of the ACE inhibitors and to show how this group differed in presentation and response to treatment from the larger population of patients with non-ACE inhibitor-related angioedema. An 8-year retrospective chart review of all patients with the diagnosis of angioedema observed from January 1, 1984 to December 31, 1991 was undertaken in the ED of an urban teaching hospital. Forty-nine patients ranging from 12 to 88 years of age with symptoms and physical examination that was consistent with the diagnosis of angioedema were entered onto the study. Twelve cases of ACE inhibitor-related angioedema were identified, all occurring in the last 4 years of the review, and when compared with the non-ACE inhibitor-related group were older (mean age, 63.3 vs 43.0 years), had less of an allergic history (0% vs 49%; P = .013), but demonstrated the same severity of symptoms and response to medical therapy. No case required an artificial or surgical airway. ACE inhibitor related angioedema is becoming a common type of angioedema observed in this ED. These patients are older and free of other allergic disease and respond well to traditional therapy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8216515     DOI: 10.1016/0735-6757(93)90166-9

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


  7 in total

1.  [Hereditary angioedema. Diagnostic and treatment errors as systemic lupus erythematosus].

Authors:  P Harten; D Körbächer; C Renk; H H Euler; H Löffler
Journal:  Med Klin (Munich)       Date:  1999-06-15

Review 2.  ACE inhibitor-induced angioedema. Incidence, prevention and management.

Authors:  W Vleeming; J G van Amsterdam; B H Stricker; D J de Wildt
Journal:  Drug Saf       Date:  1998-03       Impact factor: 5.606

3.  Factors associated with hospitalization of patients with angiotensin-converting enzyme inhibitor-induced angioedema.

Authors:  Cheng Gang; Christopher J Lindsell; Joseph Moellman; Wesley Sublett; Kim Hart; Sean Collins; Jonathan A Bernstein
Journal:  Allergy Asthma Proc       Date:  2013 May-Jun       Impact factor: 2.587

4.  A consensus parameter for the evaluation and management of angioedema in the emergency department.

Authors:  Joseph J Moellman; Jonathan A Bernstein; Christopher Lindsell; Aleena Banerji; Paula J Busse; Carlos A Camargo; Sean P Collins; Timothy J Craig; William R Lumry; Richard Nowak; Jesse M Pines; Ali S Raja; Marc Riedl; Michael J Ward; Bruce L Zuraw; Deborah Diercks; Brian Hiestand; Ronna L Campbell; Sandra Schneider; Richard Sinert
Journal:  Acad Emerg Med       Date:  2014-04       Impact factor: 3.451

Review 5.  Can an angiotensin receptor blocker be used in a patient in whom angioedema developed with an angiotensin-converting enzyme inhibitor?

Authors:  Debbie L Cohen; Raymond R Townsend
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-12       Impact factor: 3.738

6.  Angioedema.

Authors:  Allen P Kaplan
Journal:  World Allergy Organ J       Date:  2008-06       Impact factor: 4.084

7.  Angioedema: clinical and etiological aspects.

Authors:  Kanokvalai Kulthanan; Sukhum Jiamton; Kanonrat Boochangkool; Kowit Jongjarearnprasert
Journal:  Clin Dev Immunol       Date:  2007
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.